Losses widen as Evgen Pharma develops SFX-01
15th Jun 2020 09:51
(Sharecast News) - Clinical-stage drug development company Evgen Pharma reported a slight widening of its post-tax loss in its final results on Monday, to £2.7m, from £2.6m in the prior year.
Read moreEvgen Pharma narrows loss, foresees 'clinical success'
17th Dec 2019 15:35
(Sharecast News) - Evgen Pharma on Tuesday reported a narrowed interim loss and said it was confident of clinical success as it continues to develop its SFX-01 treatment.
Read moreEvgen Pharma to advance SFX-01 trial with University of Dundee
5th Dec 2019 16:36
(Sharecast News) - Clinical-stage drug development company Evgen Pharma has entered into a memorandum of understanding with the University of Dundee, it announced on Thursday, to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis (NASH) and liver fibrosis.
Read moreEvgen Pharma upbeat on latest news from SFX-01 studies
23rd Sep 2019 10:03
(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Monday that five patients who participated in the 'STEM' trial received 'SFX-01' treatment for more than one year, with two of those patients continuing to be treated with SFX-01.
Read moreEvgen Pharma completes patient study visits in 'SAS' phase 2 trial
28th Aug 2019 14:30
(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that the last study visit for the last patient entered in the double-blind, placebo-controlled 'SAS' phase 2 clinical trial has taken place.
Read moreEvgen Pharma losses edge wider on higher costs
13th Jun 2019 09:03
(Sharecast News) - Evgen Pharma on Thursday reported a slightly widened annual loss due to a cost increase, with its results in line with expectations as its drugs remain in the development stage.
Read moreEvgen Pharma's loss widens amid excitement over cancer treatment
12th Dec 2018 10:10
(Sharecast News) - Evgen Pharma's shares stumbled on Wednesday after its interim loss before tax expanded, though the company was "delighted" by progress in treatment developments.
Read moreTueday broker round-up
11th Sep 2018 12:51
(Sharecast News) - JD Wetherspoons: Berenberg upgrades to buy with a target price of 1,450p.
Read moreFriday broker round-up
27th Jul 2018 13:14
(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.
Read moreEvgen concludes patient recruitment in STEM breast cancer trial
25th Jul 2018 14:48
(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.
Read moreWednesday broker round-up
25th Jul 2018 13:57
(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.
Read moreEvgen Pharma signs service agreement with drug development corsortium
13th Feb 2017 08:21
(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulforaphane product. APT Trans, the consortium of drug developers based in the Biohub at Alderley Park, which comprises of Aptus Clinical, Apconix and Seda
Read moreRichard Moulson to join Evgen Pharma as CFO
17th Jan 2017 12:35
(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday. The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 Febru
Read moreEvgen Pharma receives go ahead for haemorrhage drug trial
11th Jan 2017 09:23
(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial
Read moreEvgen Pharma receives approval for breast cancer study
17th Aug 2016 10:49
(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer. The AIM-traded firm said patient recruitment w
Read more